JP2013510158A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510158A5
JP2013510158A5 JP2012537945A JP2012537945A JP2013510158A5 JP 2013510158 A5 JP2013510158 A5 JP 2013510158A5 JP 2012537945 A JP2012537945 A JP 2012537945A JP 2012537945 A JP2012537945 A JP 2012537945A JP 2013510158 A5 JP2013510158 A5 JP 2013510158A5
Authority
JP
Japan
Prior art keywords
composition
amino acid
period
temperature
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012537945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510158A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/055135 external-priority patent/WO2011056793A2/en
Publication of JP2013510158A publication Critical patent/JP2013510158A/ja
Publication of JP2013510158A5 publication Critical patent/JP2013510158A5/ja
Withdrawn legal-status Critical Current

Links

JP2012537945A 2009-11-03 2010-11-02 α‐1プロテイナーゼインヒビターのための組成物、方法およびキット Withdrawn JP2013510158A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25771109P 2009-11-03 2009-11-03
US61/257,711 2009-11-03
PCT/US2010/055135 WO2011056793A2 (en) 2009-11-03 2010-11-02 Composition, method, and kit for alpha-1 proteinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015175001A Division JP6030201B2 (ja) 2009-11-03 2015-09-04 α‐1プロテイナーゼインヒビターのための組成物、方法およびキット

Publications (2)

Publication Number Publication Date
JP2013510158A JP2013510158A (ja) 2013-03-21
JP2013510158A5 true JP2013510158A5 (cg-RX-API-DMAC7.html) 2013-09-26

Family

ID=43970713

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012537945A Withdrawn JP2013510158A (ja) 2009-11-03 2010-11-02 α‐1プロテイナーゼインヒビターのための組成物、方法およびキット
JP2015175001A Active JP6030201B2 (ja) 2009-11-03 2015-09-04 α‐1プロテイナーゼインヒビターのための組成物、方法およびキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015175001A Active JP6030201B2 (ja) 2009-11-03 2015-09-04 α‐1プロテイナーゼインヒビターのための組成物、方法およびキット

Country Status (19)

Country Link
US (2) US20130131192A1 (cg-RX-API-DMAC7.html)
EP (1) EP2496246B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013510158A (cg-RX-API-DMAC7.html)
KR (1) KR20120114235A (cg-RX-API-DMAC7.html)
CN (1) CN102655876B (cg-RX-API-DMAC7.html)
AU (1) AU2010315325B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012010392B8 (cg-RX-API-DMAC7.html)
CA (1) CA2779369C (cg-RX-API-DMAC7.html)
CL (1) CL2012001159A1 (cg-RX-API-DMAC7.html)
ES (1) ES2679819T3 (cg-RX-API-DMAC7.html)
HU (1) HUE039240T2 (cg-RX-API-DMAC7.html)
IL (1) IL219485A (cg-RX-API-DMAC7.html)
MX (1) MX2012005132A (cg-RX-API-DMAC7.html)
NZ (1) NZ599783A (cg-RX-API-DMAC7.html)
PL (1) PL2496246T3 (cg-RX-API-DMAC7.html)
PT (1) PT2496246T (cg-RX-API-DMAC7.html)
RU (1) RU2555332C2 (cg-RX-API-DMAC7.html)
TR (1) TR201809898T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011056793A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014007127A2 (pt) * 2011-12-30 2017-04-04 Grifols Sa métodos para retardar o início ou diminuir a progressão de um ou mais sintomas, para retardar o início ou a progressão de um ou mais sintomas, para identificar um indivíduo em necessidade de terapia de manutenção de a1pi, e para identificar indivíduos com risco elevado para exacerbações pulmonares, uso de a1pi, aparelho e meio para a administração aerossolizada de a1pi para a inalação, e, kit
IL267520B2 (en) * 2016-12-22 2023-09-01 Kamada Ltd Dry powder composition of alpha-1 antitrypsin
WO2018132874A1 (en) * 2017-01-19 2018-07-26 Csl Limited Method of preventing an immune response with alpha- 1 anti-trypsin
IL267923B2 (en) 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
US11566031B2 (en) * 2019-03-04 2023-01-31 Tae Life Sciences, Llc Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof
MX2022010087A (es) 2020-02-25 2022-09-02 Grifols Worldwide Operations Ltd Procedimiento para obtener un inhibidor de proteinasa alfa-1.

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5029005B2 (cg-RX-API-DMAC7.html) * 1972-05-08 1975-09-19
JPS51118819A (en) * 1975-04-08 1976-10-19 Green Cross Corp:The A process for preparing heat stable antitrypsin
JPS597693B2 (ja) 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4623717A (en) 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
JP2599585B2 (ja) 1984-06-19 1997-04-09 トランスジ−ン ソシエテ アノニム ヒトα▲下1▼−アンチトリプシン誘導体及びその製造法
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE3901917A1 (de) 1989-01-24 1990-07-26 Behringwerke Ag Mutanten von humanem antithrombin iii
GB8913183D0 (en) 1989-06-08 1989-07-26 Central Blood Lab Authority Chemical products
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5032405A (en) 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
JP3479539B2 (ja) 1992-04-10 2003-12-15 エーザイ株式会社 ヒトアンチトロンビンiii変異体
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
KR20010052345A (ko) 1998-05-12 2001-06-25 수잔 씨 복 인간 항트롬빈 3 및 그에 관련된 방법
CN100553678C (zh) 1999-02-22 2009-10-28 巴克斯特国际有限公司 新的无白蛋白的因子ⅷ制剂
WO2000051624A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
US20040157911A1 (en) 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
AU2001271021A1 (en) 2000-07-05 2002-01-14 Japan As Represented By Secretary Of Osaka University Process for producing glycoprotein
WO2003035051A2 (en) * 2001-10-19 2003-05-01 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
US20030235555A1 (en) 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
US7777006B2 (en) * 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
PT1664123E (pt) 2003-09-22 2008-07-16 Kamada Ltd Preparação em larga escala de um inibidor da alfa-1 proteinase e sua utilização
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
WO2005049801A2 (en) 2003-11-14 2005-06-02 Arriva Pharmaceuticals, Inc. Dry protein formulation
SI1684719T1 (sl) 2003-11-14 2012-07-31 Baxter Int Sestavki alfa antitripsina in postopki zdravljenja ob uporabi takih sestavkov
BRPI0509117A (pt) 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
BRPI0618893A2 (pt) 2005-11-22 2011-09-13 Wyeth Corp formulações de proteìna de fusão de imunoglobulina
MX2008010173A (es) 2006-02-09 2009-02-12 Kamada Ltd Antitripsina alfa-i para tratar episodios de exacerbacion de enfermedades pulmonares.
JP5810091B2 (ja) 2009-11-24 2015-11-11 グリフオルス・セラピユーテイクス・インコーポレーテツドGrifols Therapeutics,Inc. 凍結乾燥方法、組成物、及びキット

Similar Documents

Publication Publication Date Title
JP2013510158A5 (cg-RX-API-DMAC7.html)
JP2015231997A5 (cg-RX-API-DMAC7.html)
JP2011528896A5 (cg-RX-API-DMAC7.html)
JP2019504086A5 (cg-RX-API-DMAC7.html)
JP2013503110A5 (cg-RX-API-DMAC7.html)
JP2011528897A5 (cg-RX-API-DMAC7.html)
JP2013542919A5 (cg-RX-API-DMAC7.html)
JP2017222654A5 (cg-RX-API-DMAC7.html)
RU2011127913A (ru) Составы, содержащие антитела
RU2008136324A (ru) Желудочно-кишечный пролиферативный фактор и его применения
JP2024001364A5 (cg-RX-API-DMAC7.html)
JP2008536483A5 (cg-RX-API-DMAC7.html)
JP2012176978A5 (cg-RX-API-DMAC7.html)
RU2013151303A (ru) СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc
JP2008535819A5 (cg-RX-API-DMAC7.html)
RU2011140498A (ru) Препарат антител
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
JP2010202664A5 (cg-RX-API-DMAC7.html)
JP2016520075A5 (cg-RX-API-DMAC7.html)
JP2007514664A5 (cg-RX-API-DMAC7.html)
RU2013141534A (ru) Составы l-ментола, состоящие из множества частиц, и связанные с ними способы
RU2012122793A (ru) Композиция, способ и набор для альфа-1 ингибитора протеазы
JP2017113019A5 (cg-RX-API-DMAC7.html)
JP2010536714A5 (cg-RX-API-DMAC7.html)
JP2018510132A5 (cg-RX-API-DMAC7.html)